J Korean Pediatr Soc.  2000 Mar;43(3):327-334.

Anticancer Effect of Arsenic Trioxide in Acute Promyelocytic Leukemia

Affiliations
  • 1Department of Pediatrics, Keimyung University, Taegu, Korea.
  • 2Department of Microbiology, Keimyung University, Taegu, Korea.
  • 3Department of Internal Medicine School of Medicine, Keimyung University, Taegu, Korea.

Abstract

PURPOSE: Acute promyelocytic leukemia (APL or AML, M3) represents an unique model for cancer research in terms of biological and clinical features. Since 1988, it has been widely confirmed that all-trans retinoic acid (ATRA) can induce complete clinical remission in over 85% of APL patients by a differentiation process, with PML-RARalpha protein possibly being the direct target of ATRA. However, ATRA treatment has two clinical limitations, namely, retinoic acid syndrome and retinoic resistance. Recently, it has been shown that arsenic trioxide used in some traditional Chinese remedy is very effective in retinoic resistant APL treatment. We tried to observe arsenic effect on cell lines and APL patient cells. MEHTODS: We investigated arsenic trioxide-induced apoptosis on APL, HL60, K562, KPH1 cell lines through MTT assay, DNA fragmentation assay and morphologic features.
RESULTS
In MTT assay, cell survival rate decreased as the concentration of arsenic trioxide increased. In DNA fragmentation assay with HL60 cell line, DNA fragmentation was more frequent in high concentrations of arsenic trioxide than in low concentrations. During arsenic trioxide treatment, the morphologic change in bone marrow cells of APL patient, included nuclear differentiation and dark cytoplasmic granule during arsenic trioxide treatment. Serum arsenic reached peak level at 4hr after injection. We experienced a case of a 9-year-old male with APL who had relapsed after cessation of retinoic acid treatment. The patient successfully achieved remission following arsenic trioxide treatment without bone marrow depression and exacerbating bleeding diathesis.
CONCLUSION
Arsenic trioxide can be used effectively to treat APL patients by inducing apoptosis and partial differentiation in tumor cells. The precise cellular and molecular mechanisms of its therapeutic effects remain to be determined.

Keyword

Arsenic trioxide; Acute promyelocytic leukemia (APL); Childhood

MeSH Terms

Apoptosis
Arsenic*
Asian Continental Ancestry Group
Bone Marrow
Bone Marrow Cells
Cell Line
Cell Survival
Child
Cytoplasmic Granules
Depression
Disease Susceptibility
DNA Fragmentation
Hemorrhage
HL-60 Cells
Humans
Leukemia, Promyelocytic, Acute*
Male
Tretinoin
Arsenic
Tretinoin
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr